Alcidion Group Limited · ASX:ALC
Alcidion — H1 2022 Earnings Presentation
21 slides from Alcidion's earnings presentation, Feb 23, 2022
Slide 1: Investor Presentation – Half Year Results H1 FY2022
Investor Presentation Half Year Results – H1 FY2022 Kate Quirke, Group Managing Director 23 February 2022 1
Slide 2: Making the right thing to do, the easiest thing to do
Alcidion helps healthcare organisations harness the power of technology to create a clinically relevant environment with digitally enabled care… “Making the right thing to do, the easiest thing to do” 2
Slide 3: Alcidion – a Snapshot
Alcidion – a Snapshot • Alcidion has a simple purpose: To transform healthcare with Click Here to Play smart, intuitive technology solutions that improve efficiency & Introductory Video quality of patient care in healthcare organisations, worldwide • Focus on providing tools to clinicians to enable
Slide 4: Workflow of Patient Information
Workflow of Patient Information Seamlessly inter-operating with existing systems or stand alone, Alcidion enables clinicians to make better decisions • Alcidion products integrate & inter-operate with not only major EPR/EMR systems but also “specialist” applications to create a unified platform, spe
Slide 5: Product Proposition – a clinician focused offering
Product Proposition – a clinician focused offering Challenges Approach • Unlock value in existing IT investments using open standards Patient Safety with modular approach Real-time critical notifications to clinicians reduce cognitive load to minimise clinical risk & prevent poor patient outcomes •
Slide 6: Establishing a Modern, Modular EPR Offering
Establishing a Modern, Modular EPR Offering Leveraging Miya Precision platform along with recently acquired Silverlink PCS PAS, Alcidion can deliver a cloud-native modern, modular, open architecture, EPR platform taking on global vendors • Alcidion has a clear roadmap to become a leading provider of
Slide 7: H1 FY22 Summary
H1 FY22 Summary
Slide 8: H1 FY22 – Financial Summary
H1 FY22 – Financial Summary Continuing to pursue growth leading to record sold revenue heading into H2 FY22 Revenue $12.9M 16% 1 Recurring Revenue $8.8M 40% 84.8% Improvement Sold Revenue For FY22 $27.1M 25% Gross Margin 3.3pts on FY20 (88.1%) ($3.2M) Underlying EBITDA (Loss) ($5.4M) $4.5M EBITDA (L
Slide 9: H1 FY22 Operational Highlights
H1 FY22 Operational Highlights • Largest contract in Company history, $23.3M, for Commonwealth of Australia as part of Leidos Australia Consortium Milestone • $23.3M TCV over 6 years covering Miya Precision implementation & subscription fees Healthcare IT project • Potential for Miya Observations &
Slide 10: H1 FY22 Financials
H1 FY22 Financials
Slide 11: Profit & Loss - H1 FY22
Profit & Loss - H1 FY22 Profit & Loss (A$'000) H1 FY22 H1 FY21 % Change Key Comments Recurring 8,765 6,270 40% • Revenue in H1 FY22 of $12.9M, 16% increase on H1 FY21 ($11.1M) Non-Recurring 4,096 4,836 (15%) Total Revenue 12,861 11,106 16% – 68% recurring compared to 58% for same period last year Co
Slide 12: Contracted Revenue
Contracted Revenue $27.1M of FY22 Contracted Revenue at 31 December 2021 (incl. $3.8M from Silverlink) A$M Products Product Imp. Services Total Key Comments Recurring 18.7 - - 18.7 Non-recurring - 5.1 3.3 8.4 • Further $1.9M scheduled renewal revenue, expected to convert Total revenue 18.7 5.1 3.3 2
Slide 13: Balance Sheet
Balance Sheet Balance Sheet (A$'000) 31-Dec-21 30-Jun-21 Key Comments Cash & equivalents 18,938 25,027 Trade and other receivables 5,559 4,114 • $18.9M cash & no debt Other assets - prepayments 1,190 1,206 Current Assets 25,687 30,347 • $63.8M goodwill provisionally recognised in intangible assets f
Slide 14: H1 FY22 Operations
H1 FY22 Operations
Slide 15: Ongoing H1 FY22 Sales Momentum & Deployments
Ongoing H1 FY22 Sales Momentum & Deployments Recent Contract Wins Successful Deployments • Milestone $23M+ initial TCV with Commonwealth of Australia • As of 11 November 2021, ExtraMed software ‘live’ Australian • Part of UK’s first ‘Digital Control Centre’; £25m IT Government • Consortium led by Le
Slide 16: Acquisition of Silverlink
Acquisition of Silverlink Trusted provider of PAS software (a critical component of hospital IT infrastructure) to 12 NHS Trusts Business Overview Customer Overview • One of largest & last remaining specialist (standalone) PAS • Long-standing customer relationships with 12 NHS Trusts across provider
Slide 17: Expanding Alcidion's UK Market Penetration
Expanding Alcidion’s UK Market Penetration Material revenue opportunity driven by modular product upsell, along with new customer wins Alcidion NHS penetration in UK Market Contract Size Upside Potential Total Acute 38 (~26%) 145 Approx. • Current EPR offerings based on legacy tech with modern Trust
Slide 18: Australia - Market Penetration
Australia - Market Penetration Strong relationships incorporating trusted services & product offering provide foundation for expansion Alcidion penetration in AUS Market Growth Focus 1. 1 Established technical services offering holding relationships with gov’t and hospital groups provides Health 33
Slide 19: Outlook
Outlook
Slide 20: Growth Focus in FY22 and Beyond
Growth Focus in FY22 and Beyond Accelerating expansion in line with the strategy to become a global leader in healthcare technology Building • Contracted revenue for FY22 of $27.1M at 31 December 2021 (incl. $3.8M from Silverlink); 69% is recurring contracted by nature in future periods revenue base
Slide 21: Slide 21